Last reviewed · How we verify

NCT06121232

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Active, enrolled NA Last updated 17 November 2025
What this trial tests

NA trial testing Abbott® DRG / Abbott®/Medtronic® SCS in Neuropathy;Peripheral in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
2 November 2023
Primary endpoint
1 April 2026
1 April 2026

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment24
Start date2 November 2023
Primary completion1 April 2026
Estimated completion1 April 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Neuropathy;Peripheral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To learn if a process called neuromodulation can help to improve pain due to CIP

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Benefit of Tonic Versus Burst Spinal Cord Stimulation for Chemo-Induced Peripheral Neuropathy Using Psychophysical Testing
    Javed S, Kim SJ. · · 2025 · DOI 10.21203/rs.3.rs-5915887/v1

Verify or expand the search:

Other recruiting trials for Neuropathy;Peripheral

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06121232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing